Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ASCO Annual Meeting 2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

2024 ASCO Annual Meeting

Keep up to date with all the top stories and latest evidence with our hub page, including official congress videos and expert takeaways.
ADVANCED SEARCH
Log in
Top
Pathology & Oncology Research
Published in: Pathology & Oncology Research 3/2014

01-07-2014 | Research

TPX2 Overexpression in Medullary Thyroid Carcinoma Mediates TT Cell Proliferation

Authors: Xiaolin Yang, Geling Liu, Hongzhen Xiao, Fang Yu, Xiuxiu Xiang, Yifang Lu, Weijuan Li, Xiuling Liu, Sha Li, Yanping Shi

Published in: Pathology & Oncology Research | Issue 3/2014

Login to get access

Abstract

TPX2 (targeting protein for xenopus kinesin-like protein 2), a microtubule-associated protein, plays an important role in the formation of the mitotic spindle. Abnormal expression of TPX2 in various types of malignant tumors has been reported, but less is known for medullary thyroid cancer (MTC). We investigated the expression of TPX2 in human MTC tissues and its potential use as a therapeutic target. Immunohistochemical analysis of TPX2 expression was performed for 32 cases of MTC and 8 cases of normal thyroid. TPX2 expression was found to be significantly higher in MTC compared to normal thyroid tissues (P < 0.05), and to be associated with tumor size, lymph node metastasis, and advanced disease stage. The cellular effects of TPX2 knockdown, including cell proliferation, apoptosis, cell cycle diffusions, and mitotic gene expression were investigated using small interfering RNA (siRNA). TPX2-siRNA caused G1 and G2-phase cell cycle arrest, inhibited cell proliferation, and induced apoptosis. TPX2-siRNA also downregulated Aurora-A and cyclinB1 protein expression in MTC cells and enhanced the expression of p53 protein (P < 0.05). These results suggest that TPX2 may be of potential use as a new marker for MTC prognosis and therapy.
Literature
1.
Simard EP, Ward EM, Siegel R, Jemal A (2012) Cancers with increasing incidence trends in the United States: 1999 through 2008. CA Cancer J Clin 62(2):118–128
2.
Trimboli P, Ulisse S, Graziano F, Marzullo A, Ruggieri M, Calvanese A, Piccirilli F, Cavaliere R, Fumarola A, D’Armiento M (2006) Trend in thyroid carcinoma size, age at diagnosis, and histology in a retrospective study of 500 cases diagnosed over 20 years. Thyroid 16(11):1151–1155PubMedCrossRef
3.
Rahmani N, Abbas Hashemi S, Fazli M, Raisian M (2013) Clinical management and outcomes of papillary, follicular and medullary thyroid cancer surgery. Med Glas (Zenica) 10(1):164–167
4.
5.
Lin D, Ma Y, Xiao T, Guo S, Han N, Su K, Yi S, Fang J, Cheng S, Gao Y (2006) TPX2 expression and its significance in squamous cell carcinoma of lung. Zhonghua Bing Li Xue Za Zhi Chin J Pathol 35(9):540
6.
Shigeishi H, Ohta K, Hiraoka M, Fujimoto S, Minami M, Higashikawa K, Kamata N (2009) Expression of TPX2 in salivary gland carcinomas. Oncol Rep 21(2):341PubMed
7.
Mohsenifar J, Almassi-Aghdam M, Mohammad-Taheri Z, Zare K, Jafari B, Atri M, Mortazavi S-H, Azadeh P, Bagherzadeh M, Rahimi F (2007) Prognostic values of proliferative markers ki-67 and repp86 in breast cancer. Arch Iran Med 10(1):27–31PubMed
8.
Baldini E, Arlot-Bonnemains Y, Sorrenti S, Mian C, Pelizzo MR, De Antoni E, Palermo S, Morrone S, Barollo S, Nesca A, Moretti CG, D’Armiento M, Ulisse S (2011) Aurora kinases are expressed in medullary thyroid carcinoma (MTC) and their inhibition suppresses in vitro growth and tumorigenicity of the MTC derived cell line TT. BMC Cancer 11:411PubMedCentralPubMedCrossRef
9.
Schmittgen TD, Livak KJ (2008) Analyzing real-time PCR data by the comparative CT method. Nat Protoc 3(6):1101–1108PubMedCrossRef
10.
Wittmann T, Hyman A, Desai A (2001) The spindle: a dynamic assembly of microtubules and motors. Nat Cell Biol 3:E28–E34PubMedCrossRef
11.
Aguirre-Portolés C, Bird AW, Hyman A et al (2012) TPX2 controls spindle integrity, genome stability, and tumor development. Cancer Res 72(6):1518–1528PubMedCrossRef
12.
Warner SL, Stephens BJ, Nwokenkwo S, Hostetter G, Sugeng A, Hidalgo M, Trent JM, Han H, Von Hoff DD (2009) Validation of TPX2 as a potential therapeutic target in pancreatic cancer cells. Clin Cancer Res 15(21):6519–6528PubMedCentralPubMedCrossRef
13.
Tonon G, Wong K-K, Maulik G, Brennan C, Feng B, Zhang Y, Khatry DB, Protopopov A, You MJ, Aguirre AJ (2005) High-resolution genomic profiles of human lung cancer. Proc Natl Acad Sci U S A 102(27):9625–9630PubMedCentralPubMedCrossRef
14.
Sillars-Hardebol AH, Carvalho B, Tijssen M, Belien JA, de Wit M, Delis-van Diemen PM, Ponten F, van de Wiel MA, Fijneman RJ, Meijer GA (2012) TPX2 and AURKA promote 20q amplicon-driven colorectal adenoma to carcinoma progression. Gut 61(11):1568–1575PubMedCrossRef
15.
Chang H, Wang J, Tian Y, Xu J, Gou X, Cheng J (2012) The TPX2 gene is a promising diagnostic and therapeutic target for cervical cancer. Oncol Rep 27(5):1353–1359PubMed
16.
Li B, Qi XQ, Chen X, Huang X, Liu GY, Chen HR, Huang CG, Luo C, Lu YC (2010) Expression of targeting protein for Xenopus kinesin-like protein 2 is associated with progression of human malignant astrocytoma. Brain Res 1352:200–207PubMedCrossRef
17.
Morgan-Lappe SE, Tucker LA, Huang X, Zhang Q, Sarthy AV, Zakula D, Vernetti L, Schurdak M, Wang J, Fesik SW (2007) Identification of Ras-related nuclear protein, targeting protein for xenopus kinesin-like protein 2, and stearoyl-CoA desaturase 1 as promising cancer targets from an RNAi-based screen. Cancer research 67(9):4390–4398PubMedCrossRef
18.
19.
Pascreau G, Eckerdt F, Lewellyn AL, Prigent C, Maller JL (2009) Phosphorylation of p53 is regulated by TPX2-Aurora A in xenopus oocytes. J Biol Chem 284(9):5497–5505PubMedCentralPubMedCrossRef
20.
21.
Ferchichi I, Sassi Hannachi S, Baccar A et al (2013) Assessment of Aurora A kinase expression in breast cancer: A tool for early diagnosis? Dis Markers 34(2):63–69PubMedCentralPubMed
22.
Lee ECY, Frolov A, Li R, Ayala G, Greenberg NM (2006) Targeting Aurora kinases for the treatment of prostate cancer. Cancer research 66(10):4996–5002PubMedCrossRef
23.
Ulisse S, Delcros JG, Baldini E, Toller M, Curcio F, Giacomelli L, Prigent C, Ambesi-Impiombato FS, D’Armiento M, Arlot-Bonnemains Y (2006) Expression of Aurora kinases in human thyroid carcinoma cell lines and tissues. Int J Cancer 119(2):275–282PubMed
24.
Kufer TA, Silljé HH, Körner R, Gruss OJ, Meraldi P, Nigg EA (2002) Human TPX2 is required for targeting Aurora-A kinase to the spindle. J Cell Biol 158(4):617–623PubMedCentralPubMed
25.
Bayliss R, Sardon T, Ebert J, Lindner D, Vernos I, Conti E (2004) Determinants for Aurora-A activation and Aurora-B discrimination by TPX2. Cell Cycle 3(4):402–405
26.
Eyers PA, Erikson E, Chen LG, Maller JL (2003) A novel mechanism for activation of the protein kinase Aurora A. Curr Biol CB 13(8):691CrossRef
27.
Katayama H, Sasai K, Kawai H, Yuan Z-M, Bondaruk J, Suzuki F, Fujii S, Arlinghaus RB, Czerniak BA, Sen S (2003) Phosphorylation by aurora kinase A induces Mdm2-mediated destabilization and inhibition of p53. Nat Genet 36(1):55–62PubMed
28.
Liu Q, Kaneko S, Yang L, Feldman RI, Nicosia SV, Chen J, Cheng JQ (2004) Aurora-A abrogation of p53 DNA binding and transactivation activity by phosphorylation of serine 215. J Biol Chem 279(50):52175–52182PubMedCrossRef
29.
Rieder CL (2011) Mitosis in vertebrates: the G2/M and M/A transitions and their associated checkpoints. Chromosom Res 19(3):291–306CrossRef
30.
Sasayama T, Marumoto T, Kunitoku N, Zhang D, Tamaki N, Kohmura E, Saya H, Hirota T (2005) Over-expression of Aurora-A targets cytoplasmic polyadenylation element binding protein and promotes mRNA polyadenylation of Cdk1 and cyclin B1. Genes Cells 10(7):627–638PubMedCrossRef
31.
Marumoto T, Hirota T, Morisaki T, Kunitoku N, Zhang D, Ichikawa Y, Sasayama T, Kuninaka S, Mimori T, Tamaki N (2002) Roles of aurora‐A kinase in mitotic entry and G2 checkpoint in mammalian cells. Genes Cells 7(11):1173–1182PubMedCrossRef
32.
Moore JD (2013) In the wrong place at the wrong time: does cyclin mislocalization drive oncogenic transformation? Nat Rev Cancer 13(3):201–208PubMedCrossRef
Metadata
Title
TPX2 Overexpression in Medullary Thyroid Carcinoma Mediates TT Cell Proliferation
Authors
Xiaolin Yang
Geling Liu
Hongzhen Xiao
Fang Yu
Xiuxiu Xiang
Yifang Lu
Weijuan Li
Xiuling Liu
Sha Li
Yanping Shi
Publication date
01-07-2014
Publisher
Springer Netherlands
Published in
Pathology & Oncology Research / Issue 3/2014
Print ISSN: 1219-4956
Electronic ISSN: 1532-2807
DOI
https://doi.org/10.1007/s12253-014-9743-4

Other articles of this Issue 3/2014

Pathology & Oncology Research 3/2014 Go to the issue

Research

WT1 Overexpression Affecting Clinical Outcome in Non-Hodgkin Lymphomas and Adult Acute Lymphoblastic Leukemia

Research

Altered Expression of Multiple Genes Involved in Retinoic Acid Biosynthesis in Human Colorectal Cancer

Research

HIF-1α Expression Correlates with Cellular Apoptosis, Angiogenesis and Clinical Prognosis in Rectal Carcinoma

OriginalPaper

Clinicopathological Features and Prognosis of Pregnancy Associated Breast Cancer – A Matched Case Control Study

Research

Adiponectin Receptor Expression Predicts Favorable Prognosis in Cases of Hepatocellular Carcinoma

Research

Association of Genetic Polymorphisms in HSD17B1, HSD17B2 and SHBG Genes with Hepatocellular Carcinoma Risk

2024 ASCO Annual Meeting Coverage

Highlights of the Day: Breast cancer – metastatic

Breast Cancer Video

In this session, Dr. Wolff provides his key takeaways from the data presented in the metastatic breast cancer oral abstract session at ASCO 2024.

Watch now

Highlights of the Day: Gynecologic cancer

Gynecologic Cancer Video

Highlights of the Day: Breast Cancer – local/regional/adjuvant

Breast Cancer Video

Neoadjuvant dual immunotherapy improves melanoma outcomes

04-06-2024 Melanoma News

» View more highlights on the ASCO 2024 congress hub page

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits